scholarly journals Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease

2019 ◽  
Vol Volume 9 ◽  
pp. 79-88
Author(s):  
Nicoletta L. Lilli ◽  
Delphine Révy ◽  
Sandra Robelet ◽  
Béatrice Lejeune
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Neurons ◽  
In Vitro Model ◽  
Vitro Model

scholarly journals S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model

Biomedicines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1467
Author(s):  
Mariano Catanesi ◽  
Laura Brandolini ◽  
Michele d’Angelo ◽  
Maria Grazia Tupone ◽  
Elisabetta Benedetti ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mitochondrial Dysfunction ◽  
Dopaminergic Neurons ◽  
In Vitro Model ◽  
Night Time ◽  
Stress Injury ◽  
Vitro Model

The mucolytic agent S-carboxymethylcysteine is widely used as an expectorant for the treatment of numerous respiratory disorders. The metabolic fate of S-carboxymethyl-L-cysteine is complex. Several clinical studies have demonstrated that the metabolism of this agent differs within the same individual, with sulfur oxygenated metabolites generated upon night-time administration. It has been indicated that this drug behaves like a free radical scavenger and that, in this regard, the sulfide is the active species with sulphoxide metabolites (already oxidized) being inactive. Consequently, a night-time consumption of the drug should be more effective upon daytime administration. Still, this diurnal variation in biotransformation (deactivation) is dependent on the genetic polymorphism on which relies the patient population capacities of S-carboxymethyl-L-cysteine sulphoxidation. It has been reported that those cohorts who are efficient sulfur oxidizers will generate inactive oxygenated metabolites. In contrast, those who have a relative deficiency in this mechanism will be subjected to the active sulfide for a more extended period. In this regard, it is noteworthy that 38–39% of Parkinson’s disease patients belong to the poor sulphoxide cohort, being exposed to higher levels of active sulfide, the active antioxidant metabolite of S-carboxymethyl-L-cysteine. Parkinson’s disease is a neurodegenerative disorder that affects predominately dopaminergic neurons. It has been demonstrated that oxidative stress and mitochondrial dysfunction play a crucial role in the degeneration of dopaminergic neurons. Based on this evidence, in this study, we evaluated the effects of S-carboxymethyl cysteine in an in vitro model of Parkinson’s disease in protecting against oxidative stress injury. The data obtained suggested that an S-carboxymethylcysteine-enriched diet could be beneficial during aging to protect neurons from oxidative imbalance and mitochondrial dysfunction, thus preventing the progression of neurodegenerative processes.

scholarly journals L-Methionine Protects against Oxidative Stress and Mitochondrial Dysfunction in an In Vitro Model of Parkinson’s Disease

Antioxidants ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 1467
Author(s):  
Mariano Catanesi ◽  
Laura Brandolini ◽  
Michele d’Angelo ◽  
Elisabetta Benedetti ◽  
Maria Grazia Tupone ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Amino Acid ◽  
Mitochondrial Dysfunction ◽  
In Vitro Model ◽  
Methionine Sulfoxide ◽  
Methionine Sulfoxide Reductase ◽  
Vitro Model

Methionine is an aliphatic, sulfur-containing, essential amino acid that has been demonstrated to have crucial roles in metabolism, innate immunity, and activation of endogenous antioxidant enzymes, including methionine sulfoxide reductase A/B and the biosynthesis of glutathione to counteract oxidative stress. Still, methionine restriction avoids altered methionine/transmethylation metabolism, thus reducing DNA damage and possibly avoiding neurodegenerative processes. In this study, we wanted to study the preventive effects of methionine in counteracting 6-hydroxydopamine (6-OHDA)-induced injury. In particular, we analyzed the protective effects of the amino acid L-methionine in an in vitro model of Parkinson’s disease and dissected the underlying mechanisms compared to the known antioxidant taurine to gain insights into the potential of methionine treatment in slowing the progression of the disease by maintaining mitochondrial functionality. In addition, to ascribe the effects of methionine on mitochondria and oxidative stress, methionine sulfoxide was used in place of methionine. The data obtained suggested that an L-methionine-enriched diet could be beneficial during aging to protect neurons from oxidative imbalance and mitochondrial dysfunction, thus preventing the progression of neurodegenerative processes.

scholarly journals Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson’s disease

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Alysia Ross ◽  
Viktoria Xing ◽  
Ting Ting Wang ◽  
Samantha C. Bureau ◽  
Giovana A. Link ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
In Vitro Model ◽  
Membrane Depolarization ◽  
Vitro Model

Cannabidiol exerts protective effects in an in vitro model of Parkinson's disease activating AKT/mTOR pathway

Fitoterapia ◽  
2020 ◽  
Vol 143 ◽  
pp. 104553 ◽  
Author(s):  
Agnese Gugliandolo ◽  
Federica Pollastro ◽  
Placido Bramanti ◽  
Emanuela Mazzon
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
In Vitro Model ◽  
Mtor Pathway ◽  
Protective Effects ◽  
Vitro Model
Sign in / Sign up

Export Citation Format

Share Document